DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 InhibitorsPD-1 and PD-L1 Inhibitors Pipeline Landscape
' report provides comprehensive global coverage of available, marketed, and pipeline PD-1 and PD-L1 inhibitorsPD-L1 inhibitors drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PD-1 and PD-L1 inhibitorsPD-L1 inhibitors competitive domain.
200+ PD-1 and PD-L1 inhibitorsPD-L1 inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the PD-1 and PD-L1 inhibitorsPD-L1 inhibitors market would significantly increase market revenue.
ChemoCentryx, Inc. announced two upcoming poster presentations for CCX559, the Company's investigational, highly potent, orally administered PD-L1 checkpoint inhibitorPD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held November 8-12, 2022, in Boston, MA.
In
October 2022, Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum-resistant ovarian cancer, as well as data from the COM701 with or without nivolumab study in patients with metastatic NSCLC, as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.
October 2022, GSK announced positive top-line results from the PERLA phase II trial, which met its primary endpoint of objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined by blinded independent central review.
In
September 2022, Merck announced that KEYTRUDA, Merck's anti-PD-1 therapy, received four new approvals from Japan's Ministry of Health, Labor, and Welfare (MHLW).
In
July 2022, TRACON Pharmaceuticals, Inc. announced the enrollment of the 36^th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed. The interim analysis is expected to occur in the fourth quarter of this year.
In
January 2022, Merck announced that the European Commission had approved KEYTRUDA as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
PD-1 Resistant HeadPD-1 Resistant Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 resistant head and neck cancerPD-1 resistant head and neck cancer companies, including
Anti-CD279 (PD-1) Antibody Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Anti-CD279 (PD-1) antibody companies, including
PD-1 Inhibitor Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitorPD-1 inhibitor companies, including
PD-1Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 non-small cell lung cancer companies, including
PD-1Non-Small Cell Lung Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 non-small cell lung cancer companies, including
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.